Refractory Acute Lymphoblastic Leukemia (ALL) (DBCOND0069492)

Identifiers

Synonyms

Acute Lymphoblastic Leukemia Refractory / Refractory Acute lymphoblastic leukaemia / Acute, refractory Lymphocytic Leukemia / Acute, refractory Lymphoblastic Leukemia / Acute lymphocytic leukemia refractory / Acute, refractory Lymphoblastic Leukaemia / Refractory Acute Lymphoblastic Leukemia / Acute lymphocytic leukaemia refractory / Acute Lymphoblastic Leukemia, Refractory / Acute, refractory Lymphocytic leukaemia / Leukemia Lymphocytic Acute (All) Refractory

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Clofarabine	A purine nucleoside used to treat relapsed or refractory acute lymphoblastic leukemia in patients 1 to 21 years old.	DNA polymerase alpha catalytic subunittarget Ribonucleoside-diphosphate reductase large subunittarget Deoxycytidine kinaseenzyme DNAtarget Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Ribonucleoside-diphosphate reductase subunit M2target Ribonucleoside-diphosphate reductase subunit M2 Btarget
Imatinib	A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.	Platelet-derived growth factor receptor betatarget Tyrosine-protein kinase ABL1target Mast/stem cell growth factor receptor Kittarget Proto-oncogene tyrosine-protein kinase receptor Rettarget High affinity nerve growth factor receptortarget Macrophage colony-stimulating factor 1 receptortarget Platelet-derived growth factor receptor alphatarget Epithelial discoidin domain-containing receptor 1target Cytochrome P450 3A4enzyme Breakpoint cluster region proteintarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Solute carrier family 22 member 1transporter ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phospholipid-transporting ATPase ABCA3transporter Albumincarrier Alpha-1-acid glycoprotein 1carrier Bile salt export pumptransporter Cytochrome P450 2C8enzyme ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Organic cation/carnitine transporter 2transporter Solute carrier organic anion transporter family member 1B3transporter ATP-binding cassette sub-family C member 4transporter Solute carrier organic anion transporter family member 1A2transporter Discoidin domain-containing receptor 2target Induced myeloid leukemia cell differentiation protein Mcl-1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05705570	A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting
NCT05366218	Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia	Tafasitamab	treatment	1 / 2	recruiting
NCT06641024	Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL	No drug interventions	treatment	1	not_yet_recruiting
NCT03576547	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	Dexamethasone Ponatinib Rituximab Venetoclax	treatment	1 / 2	completed
NCT05761171	A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	Asparaginase Escherichia coli Benzalkonium Calaspargase pegol Carbonate ion Cortisone Cytarabine Ethanol Fludarabine Hydrocortisone Hydrocortisone succinate Methopterin Methotrexate Prednisolone Prednisone Revumenib Sodium succinate Sulfate ion Vincristine	treatment	2	recruiting
NCT02727803	Personalized NK Cell Therapy in CBT	Activated natural killer cell therapy Aloe vera leaf Ascorbic acid Busulfan CD-16 NK-92 cells Clofarabine Cyclophosphamide Fludarabine Glycerin Mechlorethamine Natural Killer Cell Nicotinamide Rituximab Vitamin A	treatment	2	recruiting
NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	Fludarabine	treatment	1	suspended
NCT03519984	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia	Cytarabine SEphB4-HSA Vincristine	treatment	1	terminated
NCT02199184	Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia	Beta-D-Glucose Cortisone Cyclophosphamide Doxorubicin Etoposide Ofatumumab Prednisone Rituximab Sulfate ion Vincristine	treatment	2	completed
NCT06447987	Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia	Cetuximab Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT03132454	Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia	Decitabine Dexamethasone Palbociclib Sorafenib	treatment	1	recruiting
NCT04000698	Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias	No drug interventions	treatment	3	unknown_status
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT04325841	Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children	No drug interventions	treatment	2	recruiting
NCT06316427	Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma	No drug interventions	treatment	1 / 2	recruiting
NCT04996160	Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)	Bortezomib Dexamethasone Doxorubicin Palbociclib	treatment	1	recruiting
NCT03504644	Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	Venetoclax Vincristine	treatment	1 / 2	recruiting
NCT02392572	ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome	Dordaviprone	treatment	1 / 2	recruiting
NCT04888468	Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents	No drug interventions	treatment	1	completed
NCT03136146	Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Clofarabine Cyclophosphamide Dexamethasone Etoposide Filgrastim Ofatumumab Pegfilgrastim Rituximab Vincristine	treatment	2	recruiting
NCT03147612	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia	Blinatumomab Cyclophosphamide Cytarabine Filgrastim Methopterin Methotrexate Muromonab Pegfilgrastim Ponatinib Rituximab Vincristine	treatment	2	active_not_recruiting
NCT06581081	Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia, a Prospective, Open, Multicenter, Randomized, Control Study	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT03349281	Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL	Asparaginase Escherichia coli Cytarabine Dexamethasone Doxorubicin Hydrocortisone Methotrexate Pegaspargase Pevonedistat Vincristine	treatment	1	completed
NCT05334823	A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents	No drug interventions	treatment	2	recruiting
NCT04012879	Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia	No drug interventions	treatment	1	unknown_status
NCT05679687	ThisCART19A Bridging to alloHSCT for R/R B-ALL	No drug interventions	treatment	1	recruiting
NCT03512405	Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia	Blinatumomab Muromonab Pembrolizumab	treatment	1 / 2	recruiting
NCT06287528	A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)	No drug interventions	treatment	1	recruiting
NCT03094611	Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia	Inotuzumab ozogamicin	treatment	2	terminated
NCT05418088	Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT01658007	Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma	Sirolimus	treatment	0	terminated
NCT06316856	CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	recruiting
NCT02220985	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	Cyclophosphamide Fludarabine Methopterin Methotrexate Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT04888442	Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL	No drug interventions	treatment	1	unknown_status
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Flotetuzumab	treatment	2	withdrawn
NCT02551718	High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia	No drug interventions	treatment	Not Available	completed
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT04139434	Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML	Azacitidine	treatment	1	active_not_recruiting
NCT03128034	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	suspended
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT02146924	Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia	No drug interventions	treatment	1	active_not_recruiting
NCT01620216	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia	Dasatinib Idelalisib Pacritinib Ponatinib Ruxolitinib Sorafenib Sunitinib	treatment	2	terminated
NCT03620058	CART22 Alone or in Combination With huCART19 for ALL	No drug interventions	treatment	1	active_not_recruiting
NCT04752163	DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	Azacitidine Coenzyme M Cortisone Cyclophosphamide Cytarabine Dexamethasone Filgrastim Leucovorin Methopterin Methotrexate Methoxamine Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole	treatment	1 / 2	completed
NCT03575325	Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia	Cytarabine Daunorubicin	treatment	2	completed
NCT03670966	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	Cyclophosphamide Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	1 / 2	suspended
NCT03096782	Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	Aloe vera leaf Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Ascorbic acid Busulfan Clofarabine Cyclophosphamide Filgrastim Fludarabine Glycerin Mechlorethamine Mycophenolate mofetil Nicotinamide Rituximab Tacrolimus Vitamin A	treatment	2	completed
NCT05192889	Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax	Asparaginase Erwinia chrysanthemi Asparaginase Escherichia coli Blinatumomab Calaspargase pegol Cyclophosphamide Cytarabine Dasatinib Dexamethasone Etoposide Hydrocortisone Leucovorin Mercaptopurine Methotrexate Navitoclax Pegaspargase Venetoclax Vincristine	treatment	1 / 2	active_not_recruiting
NCT04562792	Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia	Daunorubicin	treatment	2	completed
NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04340167	Study of Anti-CD22 CAR-T Cells Treating Leukemia Children	No drug interventions	treatment	2	recruiting
NCT03263572	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	Blinatumomab Cytarabine Methopterin Methotrexate Muromonab Ponatinib	treatment	2	recruiting
NCT04526795	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia	Cytarabine Fludarabine Pegcrisantaspase	treatment	1	active_not_recruiting
NCT02143414	Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia	Blinatumomab Cortisone Dasatinib Mercaptopurine Methopterin Methotrexate Muromonab Prednisone Sulfate ion Vincristine	treatment	2	active_not_recruiting
NCT04603872	CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies	Dasatinib	treatment	0	recruiting
NCT03573700	Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia	Coenzyme M Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT04881240	Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia	Coenzyme M Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT02091245	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	Selinexor	treatment	1	active_not_recruiting
NCT04037566	CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.	Cyclophosphamide Fludarabine	treatment	1	unknown_status